Automated and Closed Cell Therapy Processing System Industry Rising at a CAGR of 23.45% by 2032

The global automated and closed cell therapy processing system industry revenue will gain around USD 8,201.33 million by 2032 from USD 997.4 million in 2022 and is growing at a remarkable CAGR of 23.45% from 2023 to 2032.

Market Growth:

With its customized and individualized approach, CAR T-cell therapy is transforming the way cancer is treated and has helped many patients achieve long-term remission. Manufacturers are searching for ways to scale and optimize the production process in order to reduce costs and satisfy regulatory requirements while a continual supply of new treatments enters the trial pipeline. Using automated, closed systems with integrated software controls is one method for reducing some of the present obstacles in production. Compared to conventional open systems, these systems can provide a number of advantages, including process standardization, cheaper manufacturing costs, improved batch-to-batch uniformity, and less risk of contamination.

The demand for automated and closed-cell treatment processing systems has risen as cancer incidence rates rise globally. The goal of completely automated cell therapy processing systems is to achieve reliable processing with better treatments for illnesses that are largely incurable.

Furthermore, the Covid-19 epidemic has brought attention to the benefits of stem cell treatment. During the forecast period, advances in stem cell therapies are anticipated to continue, supporting the expansion of the industry for automated and closed cell therapy processing systems.

Regional Snapshot:

Nearly 46% of the industry for automated and closed cell therapy processing systems is dominated by North America. One important reason for the region's dominant position is said to be the region's quick adoption of sophisticated automated cell therapy manufacturing methods. During the anticipated period, Asia Pacific is anticipated to have a sizable industry share for automated and closed cell therapy processing systems. The automation of cell therapy manufacturing systems has a great deal of potential in Japan, which will support the industry's expansion in the Asia Pacific region.

During the period of forecasting, the industry for automated and closed cell therapy processing systems is expected to expand in the UK.  The expansion of the industry in Europe is projected to be supported by the well-established pharmaceuticals industry and increasing research & development activity in the biotech sector. The industry will expand at a notable rate as a result of the increased demand for personalized medications in the area.

Automated and Closed Cell Therapy Processing System Industry Report Scope:

Market Dynamics:

Drivers:

The value of automation in GMP production

Automation of the workflow may remove a wide range of problems and can be a crucial component of large-scale cGMP production as a complement to the integration of closed manufacturing equipment. "The use of automated equipment may ease compliance with certain GMP requirements and may also bring certain advantages in respect to product's quality," the EMA recommends.

Automation would increase worker safety, decrease human error, and allow for processing robustness and repeatability. Overall operations can be made simpler by automated systems. A single operator can merge multiple-step or multiple-operator manual processes into one machine, speeding up product turnover and lowering the number of workers needed in the workspace. As a result, the capacity of the facility will increase.

Restraints:

Insufficient raw material

There are several phases in the manufacturing process for cell therapies, and each one needs a starting point. Raw materials required for best medical practice are in short supply due to the global increase in demand for automated and closed-cell therapy processing systems. (GMP). Plasmids and viral vectors, which are proven GMP-based raw materials used in the cell therapy process, are hard to come by due to the industry's rapid growth in cell treatments and the rise of chronic illnesses. In addition to this, the difficulties in getting raw materials like bone marrow, blood, and apheresis provide a problem for the industry's expansion.

Opportunities:

The pharmaceutical industry is engaging in more research and development.

To speed up the development of new therapies for a variety of medical diseases, governments, and big pharmaceutical corporations are investing in research and development operations. By promoting the development of innovative automated and closed-cell treatments, the increased investment in R&D activities for the discovery of cell therapies will boost the industry's expansion. Additionally, the expanding R&D efforts in the pharmaceutical industry are projected to significantly increase industry revenue.

Non-Stem Cell Therapy:

With a predicted period, the industry for non stem cell therapy expanded. The development of non-stem cell treatments has received more funding as a result of the success of CAR-T therapies, increasing industry income. To develop innovative regenerative medicines for the management of chronic illnesses, businesses are actively partnering and forging alliances.

These research projects are mostly concerned with non-stem cell applications, which is promoting the growth of the non-stem cell therapy industry. Additionally, the category is anticipated to grow at a quicker rate throughout the forecast period due to the huge therapeutic potential of cell and tissue-based engineering.

Recent Development:

• In February 2023, IASO Biotherapeutics, a clinical-stage biopharmaceutical company that creates cutting-edge cell therapies, announced that the U.S. Food and Drug Administration (FDA) had given its new BCMA CAR-T CT103A (Equecabtagene Autoleucel) drug Fast Track (FT) Designation and Regenerative Medicine Advanced Therapy (RMAT) Designation. Relapsed/refractory multiple myeloma (RRMM), a serious form of blood cancer that stops responding to cell therapy, can be treated with medication. 
• In February 2023, Cell and Gene Therapy Catapult, an independent UK organization for innovation and technology, declared its involvement in the construction of a sizeable new life science campus in Stevenage. About 900 million euros have been set aside by the firm to create the new site. In order to satisfy the huge demand from life sciences businesses, a new campus was built.  
• In February 2023, Athersys Inc., a well-known cell therapy and regenerative medicine firm, declared that the FDA has approved a clinical type B meeting for discussing protocol. By taking this action, the corporation hopes to improve its skills in the advanced MASTERS-2 clinical trials. 
• In April 2022, In order to produce exploratory CAR-T cell immunotherapy, City of Hope, one of the largest cancer research and treatment institutions in the U.S., planned to include Curate Biosciences' Curate Cell Processing System into its workflow. The business thinks that by incorporating this cell processing technique, T-cell separation will be approached in a novel way.

Major Key Players:

• Lonza
• BioSpherix
• Cellares
• Sortorius
• Cytiva
• ThermoGenesis Holdings Inc
• Thermo Fisher Scientific Inc

Market Segmentation:

By Workflow

• Cryopreservation
• Fill-finish
• Separation
• Expansion
• Apheresis
• Others 

By Type

• Stem Cell Therapy
• Non-stem Cell Therapy

By Scale

• Commercial Scale
• R&D Scale

Buy this Research Report@ https://www.precedenceresearch.com/checkout/2653

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333